| domain | established finding | evidence strength | suggested ontology/database annotation |
|---|---|---|---|
| Identity | Epsilon-N-trimethyllysine hydroxylase deficiency refers to deficiency of TMLHE, the enzyme catalyzing the first step of endogenous carnitine biosynthesis; current human literature supports a biochemical defect and possible neurodevelopmental risk state rather than a uniformly defined, fully penetrant Mendelian syndrome (pqac-00000001, pqac-00000002) | Moderate for biochemical identity; low-moderate for syndrome definition | Gene: **TMLHE**; pathway/database: carnitine biosynthesis; disease ontology term/ID: **MONDO ID verification needed** |
| Gene / locus / inheritance | **TMLHE** is located on **Xq28**; reported pathogenic or likely deleterious events are **germline** hemizygous variants/deletions in males, consistent with **X-linked** inheritance (pqac-00000001, pqac-00000004) | Moderate | HGNC: **TMLHE**; chromosomal location: **Xq28**; inheritance: **X-linked inheritance (HP:0001417)** |
| Molecular defect | Reported human variants include **c.229C>T (p.Arg77\*)**, **c.730G>C (p.Asp244His)**, and **c.1107G>T / p.Glu369Asp**; functional work indicated **loss of function**, including markedly reduced mRNA for the nonsense allele (pqac-00000000, pqac-00000001, pqac-00000004) | Moderate | Variant classes: nonsense, missense, exon deletion; sequence databases: ClinVar/OMIM **ID verification needed** |
| Biochemical defect | Deficiency blocks the first step of carnitine biosynthesis from trimethyllysine, producing substrate accumulation; plasma **trimethyllysine (TML)** was increased about **2-3-fold** in affected individuals, while free carnitine was mildly decreased or within normal range in reported cases (pqac-00000000, pqac-00000001) | Moderate | CHEBI: **L-carnitine (CHEBI:16347)**; metabolite term for trimethyllysine: **CHEBI ID verification needed** |
| Biomarkers | Most established biomarker is **elevated plasma trimethyllysine**; reduced TMLHE transcript/protein activity is supportive in research settings; carnitine concentration alone may be insensitive because endogenous synthesis contributes only part of total body carnitine supply (pqac-00000000, pqac-00000003) | Moderate for TML; low for broader biomarker panel | Laboratory abnormality annotation: elevated trimethyllysine **HPO term/ID verification needed**; metabolomics/database: targeted plasma amino-acid/acylcarnitine or LC-MS/MS profiling |
| Reported phenotypes | Human reports link TMLHE deficiency/variants mainly to **autism spectrum disorder** and sometimes **intellectual disability**, especially in affected males from multiplex autism families; evidence supports susceptibility association, not phenotype specificity (pqac-00000000, pqac-00000002, pqac-00000004) | Low-moderate | HPO: **Autistic behavior (HP:0000729)**; **Intellectual disability (HP:0001249)** |
| Penetrance / prevalence caveat | Available evidence indicates **low penetrance** for neurodevelopmental disease. One study cited exon 2 deletion in **3/691 ASD males vs 1/896 male controls** and estimated penetrance around **2-4%**; statistical support was limited and authors treated TMLHE deficiency as a **risk factor/susceptibility factor**, not a deterministic cause (pqac-00000000, pqac-00000001) | Moderate for caveat; low for precise penetrance | Population genetics resources: gnomAD/ClinVar **ID verification needed**; disease characterization: susceptibility/risk factor annotation rather than fully penetrant monogenic disease |
| Diagnosis | Best-supported diagnostic approach is **molecular testing of TMLHE** together with **targeted biochemical testing** showing elevated plasma trimethyllysine; array CGH/exome sequencing can detect exon deletions or sequence variants (pqac-00000002, pqac-00000004) | Moderate | Testing modalities: single-gene sequencing, exome sequencing, CNV analysis/array CGH; GTR/OMIM **ID verification needed** |
| Treatment evidence | No established standard therapy or trial-supported disease-modifying treatment was identified. Literature cited a **single case report** describing improvement in regressive autism symptoms after **L-carnitine supplementation**, but this remains **case-level, non-confirmatory evidence** (pqac-00000005) | Low | NCIT: **Levocarnitine / L-carnitine ID verification needed**; supportive care annotation |
| Prognosis | Natural history, long-term outcomes, mortality, and genotype-phenotype correlations are **not well established** because published human cases are few and phenotypes are heterogeneous (pqac-00000000, pqac-00000001) | Low | Prognosis/natural history: **data not established** |
| Model / mechanistic context | Mechanistic interpretation centers on reduced endogenous carnitine biosynthesis and possible downstream effects on mitochondrial fatty-acid oxidation/brain energetics; Drosophila and other model discussions provide biologic plausibility, but direct disease-model evidence specific to human TMLHE deficiency is limited in the retrieved evidence (pqac-00000005) | Low-moderate | GO biological process: **carnitine biosynthetic process**; cellular component/process IDs **verification needed** |
| Major unknowns | Unresolved issues include whether TMLHE deficiency constitutes a distinct Mendelian disease entity, true population prevalence, full biomarker spectrum beyond TML, penetrance modifiers, sex-specific expressivity, treatment responsiveness, and whether newborn or carrier screening is clinically justified (pqac-00000000, pqac-00000001, pqac-00000005) | High confidence that these are unknowns | Knowledge-base flags: evidence gap; **ID verification needed** for disease ontology mapping |


*Table: This compact table summarizes what is currently established, uncertain, and clinically actionable about epsilon-N-trimethyllysine hydroxylase deficiency. It is designed for direct use in a disease knowledge base, with evidence strength and suggested ontology/database annotations.*